702 DUAL BLOCKADE OF THE PD-1 CHECKPOINT PATHWAY AND THE ADENOSINERGIC NEGATIVE FEEDBACK SIGNALING PATHWAY WITH A PD-1/CD73 BISPECIFIC ANTIBODY FOR CANCER IMMUNE THERAPY